

**Remarks/Arguments**

Applicants have amended the specification to provide the priority claim. The claims have been amended to remove multiple dependencies, correct certain typographical errors, to add certain new claims and to otherwise place the claims in an appropriate U.S. format.

Specifically:

- Claim 1 has been amended to correct a typographical error in the spelling of "groups" (in R<sup>3</sup>), "substituents" (in R<sup>4</sup>) and "phosphonooxy" (in R<sup>10</sup>);
- Claim 4 has been amended to correct a typographical error in "compounds" and to remove the multiple dependencies.
- Claims 5-8, 10-11 and 13 have been amended to correct multiple dependencies;
- Claims 14-17 have been cancelled;
- Claims 18-20 have been amended to make the language consistent with other claims;
- Claim 21 has been added; basis for this claim is original claim 16;
- Claim 22 has been added; basis for this claims is to be found in the specification on page 11 line 26 to page 12 line 13,
- Claim 23 has been added; basis for this claims is to be found in the specification on page 12 line 28 to page 13 line 8;
- Claim 24 has been added; basis for this claims is to be found in the specification on page 13 line 23 to page 14 line 3; and
- Claim 25 has been added; basis for this claim is original claim 13;


No new matter has been added by these amendments.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100938 1P-US.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Lucy Padget", is written over a horizontal line.

Name: Lucy Padget  
Dated: June 17, 2005  
Reg. No.: Limited Recognition  
Phone No.: 781-839-4182  
Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatehouse Drive,  
Waltham,  
MA 01760